Executive Summary
Vernalis plc (formerly British Biotech) is a specialty pharmaceutical company focused on products marketed to specialist neurologists. The Company has two marketed products, Frova(R) and Apokyn(R), and a development pipeline focused on neurology and central nervous system disorders. The company has six products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono. Vernalis has established a U.S. commercial operation to promote Apokyn(R) and co-promote Frova(R) alongside its North American licensing partner, Endo Pharmaceuticals, propelling the Company towards its goal of becoming a sustainable, self-funding, R&D-driven, specialty pharmaceutical company.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
